SCHEMBL546475

SCHEMBL546475

CC(C)(C)OC(=O)N1CCC(NCCC(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
MAPT P10636 2/20 0.54
MAPK1 P28482 2/20 0.54
NPC1 O15118 1/20 0.54
HTT P42858 1/20 0.54
RAB9A P51151 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 2/20 0.53
PKM P14618 1/20 0.53
GPR119 Q8TDV5 2/20 0.52
USP30 Q70CQ3 3/20 0.52
STS P08842 1/20 0.50
CHRM2 P08172 1/20 0.49
CHRM5 P08912 1/20 0.49
CHRM3 P20309 1/20 0.49
EPHX1 P07099 1/20 0.49
SOS1 Q07889 1/20 0.49
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981183 0.86 KDM4E (0.67) ALDH1A1KDM4ECHRM2CHRM5CHRM3
SCHEMBL3641876 0.84 KDM4E (0.56) ALDH1A1MAPTMAPK1NPC1HTT
SCHEMBL22467690 0.84 KDM4E (0.55) ALDH1A1MAPTMAPK1NPC1HTT
SCHEMBL6498471 0.84 KDM4E (0.55) ALDH1A1MAPTMAPK1NPC1HTT
SCHEMBL21074855 0.84 KDM4E (0.55) ALDH1A1MAPTMAPK1NPC1HTT
SCHEMBL2106890 0.83 STS (0.57) ALDH1A1KDM4EPKMGPR119USP30
SCHEMBL2430029 0.83 USP30 (0.56) KDM4EPKMGPR119USP30
SCHEMBL2430031 0.83 USP30 (0.56) KDM4EPKMGPR119USP30
SCHEMBL8311276 0.82 SOS1 (0.58) KDM4ECHRM2CHRM5CHRM3SOS1
SCHEMBL5576515 0.81 EPHX1 (0.53) ALDH1A1MAPTMAPK1NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324396-B2 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. (US) 2012-12-04 US disclosed
US-8324396-B2 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. (US) 2012-12-04 US disclosed
US-8110574-B2 Derivatives of 4-aminopiperidine and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2012-02-07 US disclosed
US-8110574-B2 Derivatives of 4-aminopiperidine and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2012-02-07 US disclosed
US-8110574-B2 Derivatives of 4-aminopiperidine and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2012-02-07 US disclosed
US-20110059971-A1 DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT IPSEN S.A.S. (FR) 2011-03-10 US disclosed
US-20110059971-A1 DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT IPSEN S.A.S. (FR) 2011-03-10 US disclosed
US-20110059971-A1 DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT IPSEN S.A.S. (FR) 2011-03-10 US disclosed
US-7858789-B2 Derivatives of 4-aminopiperidine and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2010-12-28 US disclosed
US-7858789-B2 Derivatives of 4-aminopiperidine and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2010-12-28 US disclosed
US-20090149652-A1 Derivatives of 4-aminopiperidine and their use as a medicament SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES 2009-06-11 US disclosed
US-20090054463-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. 2009-02-26 US disclosed
US-20090054463-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor AMGEN INC. 2009-02-26 US disclosed
EP-1286966-B1 4-AMINOPIPERIDINE DERIVATIVES AND THEIR USE AS MEDICINE SOD CONSEILS RECH APPLIC (FR) 2008-07-16 EP disclosed
US-7393861-B2 Derivatives of 4-aminopiperidine and their use as a medicament SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2008-07-01 US disclosed
US-7393861-B2 Derivatives of 4-aminopiperidine and their use as a medicament SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2008-07-01 US disclosed
US-7393861-B2 Derivatives of 4-aminopiperidine and their use as a medicament SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2008-07-01 US disclosed
US-7115634-B2 4-aminopiperidine and their use as a medicine SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 2006-10-03 US disclosed
US-20050239796-A1 Derivatives of 4-aminopiperidine and their use a medicament SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) 2005-10-27 US disclosed
US-20040006089-A1 4-Aminopiperidine and their use as a medicine IPSEN PHARMA S.A.S. (FR) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149652-A1 Derivatives of 4-aminopiperidine and their use as a medicament SSTR4, SSTR3, SSTR1 ALDH1A1 1795/4885MAPT 4005/4885MAPK1 1837/4885
US-20050239796-A1 Derivatives of 4-aminopiperidine and their use a medicament SSTR4, SSTR3, SSTR2 ALDH1A1 1681/4885MAPT 4149/4885MAPK1 1800/4885
US-20040006089-A1 4-Aminopiperidine and their use as a medicine SSTR1, SSTR2, SSTR4 ALDH1A1 1428/4885MAPT 4467/4885MAPK1 1044/4885
US-20090054463-A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor UTS2R, CASR, GPR17 ALDH1A1 785/4885MAPT 1435/4885MAPK1 724/4885
US-20110059971-A1 DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT SSTR4, SSTR3, SSTR1 ALDH1A1 1795/4885MAPT 4005/4885MAPK1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.